Description

PRO20 is a potent and highly selective peptide antagonist of the (pro)renin receptor (PRR). By competitively inhibiting prorenin-induced calcium influx (IC50: 81 nmol/L), PRO20 plays a crucial role in research focused on the renin–angiotensin system (RAS) and its contribution to cardiovascular diseases, particularly hypertension.

The renin–angiotensin system is a well-established regulator of blood pressure, fluid balance, and vascular tone. Overactivation of this pathway, often driven by excessive prorenin–PRR binding, contributes to elevated angiotensin II (Ang II) production, vasoconstriction, and hypertensive pathology. PRO20, by blocking PRR interaction, prevents downstream activation of the RAS, reducing Ang II formation and associated hypertensive signaling.

Researchers have found PRO20 to be especially valuable in:

• Exploring novel antihypertensive strategies

• Studying renin–angiotensin system mechanisms

• Investigating calcium signaling pathways

• Evaluating the potential of PRR antagonism in cardiovascular models

Manufactured under strict GMP-grade standards, PRO20 ensures consistent purity (98.32%) and reliability for laboratory investigations. It is available for both bulk wholesale supply and smaller-scale retail laboratory purchases.

Note: PRO20 is strictly intended for laboratory and experimental use. It is not approved for human or veterinary applications.

Product Specifications

Mechanism of Action & Research Applications

PRO20 functions as a competitive PRR antagonist, directly blocking prorenin from binding to its receptor. Normally, prorenin binding to PRR initiates calcium influx within cells, which contributes to the activation of intracellular signaling cascades and downstream production of Ang II through the renin–angiotensin system. By preventing this interaction, PRO20 effectively reduces the excessive production of Ang II, one of the key drivers of vasoconstriction and hypertension.

Key Mechanistic Insights:

• Calcium Regulation: PRO20 blocks prorenin-induced calcium influx, thereby influencing intracellular calcium dynamics crucial for cell signaling.

• Renin–Angiotensin System Modulation: It prevents the pathological overactivation of RAS, reducing Ang II generation.

• Vascular Effects: By lowering Ang II signaling, PRO20 reduces vasoconstriction and pathological vascular remodeling in experimental models.

• Antihypertensive Potential: Studies highlight its promise as a candidate molecule for research into novel blood pressure regulation strategies.

Research Applications:

• Hypertension Models: Used in experimental systems to test the effect of PRR blockade on blood pressure regulation.

• Cardiovascular Research: Provides a valuable tool for understanding the role of PRR in heart and vascular disease progression.

• Renin–Angiotensin Studies: Enables deeper study of prorenin, renin, and angiotensin interactions in cellular and animal models.

• Drug Discovery: Serves as a lead compound or control peptide in the development of next-generation antihypertensive agents.

With its defined purity and reproducibility, PRO20 is widely adopted in cardiovascular laboratories seeking to clarify RAS-related mechanisms.

Side Effects (For Reference in Research Models Only)

In laboratory research contexts, PRO20 has been associated with the following observations:

• Reduction of blood pressure in hypertensive models

• Modulation of calcium-dependent signaling pathways

• Alteration of renin and Ang II activity

Since PRO20 is strictly for research use, no human or clinical side effects are documented. Reported effects are derived solely from experimental and preclinical studies.

Disclaimer

 is provided exclusively for laboratory research and development use. It is not intended for human or veterinary applications, medical treatment, or diagnostic procedures.More products